Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer

被引：10
|
作者：
Wan, Guoxing [1 ]
Cao, Fengjun [1 ]
Wang, Xuanbin [1 ]
Sun, Xue [1 ]
机构：
[1] Hubei Univ Med, Renmin Hosp, Dept Oncol, 39 Chaoyang Rd, Shiyan 442000, Peoples R China
来源：
JOURNAL OF CANCER | 2019年 / 10卷 / 02期
关键词：
CYCLOPHOSPHAMIDE; SURVIVAL;
D O I：
10.7150/jca.29461
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：416 / 417
页数：2
相关论文
共 50 条
  • [1] Bevacizumab in HER2-negative non-metastatic breast cancer
    Bennet, Neil
    [J]. LANCET ONCOLOGY, 2012, 13 (03): : E93 - E93
  • [2] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [3] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    [J]. CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [4] The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
    Al-Shamsi, Humaid O.
    Ibrahim, Nuhad K.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S694 - S696
  • [5] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [6] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    [J]. Breast Cancer, 2017, 24 : 63 - 68
  • [7] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
  • [8] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    [J]. BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [9] Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis
    Wang, Bi-Cheng
    Fu, Chen
    Xie, Lin-Ka
    Kuang, Bo-Hua
    Zhao, Yan-Xia
    [J]. ANNALS OF PHARMACOTHERAPY, 2020, 54 (06) : 517 - 525
  • [10] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
12345